FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of After being placed into FDA Category 2 in 2023, several widely discussed peptides faced restricted pathways for regulated compounding. This shift pushed demand toward unregulated markets and created significant uncertainty across the FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them